BBIO - BridgeBio Corp Revenue Dynamics YoY (Last Twelve Months)

Graphic logo of BridgeBio Corp (BBIO)

BridgeBio Pharma, Inc. (BBIO) relies on volatile licensing revenues during a period of active genetic therapy development. Capital pressure is driven by the complexities of bringing orphan drugs to market and expensive borrowing costs. Geopolitical instability further restricts global testing. Annual revenue growth on a TTM basis demonstrates development dynamics, where the parameter value equals 166.50.

BBIO BridgeBio Pharma: Sales Growth YoY (Last Twelve Months) in the range 02/11/2024 - 11/17/2026

bridgebio.com (BBIO) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
- market capitalization statistics:
Summary company analytics:BridgeBio Corp (BBIO)
Mass-produced product of BridgeBio Pharma, Inc.

Expectations regarding the market launch of BridgeBio Pharma (BBIO) leading cardiovascular drug are already partially priced in, while the potential of new developments is only beginning to unfold. The current value of 166.50 reflects the daily percentage growth of commercial revenues over a rolling year, allowing for an assessment of business scaling dynamics relative to debt load through changes in TTM 12-month year-over-year revenue.

Competitors of BridgeBio Pharma, Inc. (BBIO)